
|Videos|November 4, 2021
Targeted Therapies Are Impacting the Treatment of NETs
Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses how targeted therapies are impacting the treatment of NETs.
Advertisement
In a Pharmacy Times® interview, Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, about her presentation on neuroendocrine tumor (NETs) management in large cancer centers at the NANETS 2021 Conference.
She discussed how targeted therapies are impacting the treatment of NETs.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants National Priority Vouchers to Enlicitide Decanoate, Sacituzumab Tirumotecan
2
Beyond Injections: Orforglipron and the Future of Oral GLP-1 Receptor Agonist Therapy
3
Toothpaste Tablets Are Gaining Popularity—Here’s Where Pharmacists Fit In
4
Twists, Turns, and Tapers: Navigating the Benzodiazepine Ride
5













































































































































































































